These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9559850)

  • 1. Nephrogenic adenoma in a patient with transitional cell carcinoma of the bladder receiving intravesical bacillus Calmette-Guérin.
    Oyama N; Tanase K; Akino H; Mori H; Kanamaru H; Okada K
    Int J Urol; 1998 Mar; 5(2):185-7. PubMed ID: 9559850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment: a report of 2 cases.
    Stilmant MM; Siroky MB
    J Urol; 1986 Feb; 135(2):359-61. PubMed ID: 3511292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.
    Bajramovic S; Alic J; Skopljak E; Chikha A; Vesnic S; Smajilbegovic V; Aganovic D
    Med Arch; 2020 Apr; 74(2):146-150. PubMed ID: 32577059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
    Hillyard RW; Ladaga L; Schellhammer PF
    J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade transitional cell carcinoma of the bladder in a 5-year-old boy successfully treated with partial cystectomy and intravesical bacillus Calmette-Guerin.
    Khandelwal P; Brewer AJ; Minevich E; Miles L; Geller JI
    J Pediatr Hematol Oncol; 2014 May; 36(4):e234-6. PubMed ID: 23619109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic adenoma of the bladder after intravesical bacillus Calmette-Guérin treatment.
    Kilciler M; Tan O; Ozgök Y; Tahmaz L; Deveci S; Erduran D
    Urol Int; 2000; 64(4):229-32. PubMed ID: 10895092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report.
    Hakim S; Heaney JA; Heinz T; Zwolak RW
    J Urol; 1993 Jul; 150(1):188-9. PubMed ID: 8510250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].
    Hagiwara M; Asano T; Iigaya T; Tsukamoto T; Nishida K
    Nihon Hinyokika Gakkai Zasshi; 1986 Oct; 77(10):1623-30. PubMed ID: 3820900
    [No Abstract]   [Full Text] [Related]  

  • 16. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleural effusion after intravesical administration of bacillus Calmette-Guérin.
    Roca Noval A; Cisneros C; García-Pérez FJ; Domingo D
    Arch Bronconeumol; 2017 Dec; 53(12):694-695. PubMed ID: 28476221
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.